Go offline with the Player FM app!
Commercial Readiness with ImmunityBio's Bobby Reddy, M.D.
Manage episode 412653666 series 2739469
We love to hear from our listeners. Send us a message.
This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical Officer at ImmunityBio, gives us a long look behind the curtain at the commercial preparations the company is making as its lead Phase 3 candidate, Anktiva, nears the goal line in non-muscle invasive bladder cancer (NMIBC). From grassroots engagement with physicians and urologists to making a global press to share clinical results, Dr. Reddy offers plenty of insight into biopharma commercial readiness, and good reason to hope for nearly a million NMIBC patients in the U.S. alone.
Register for Bioprocess Online’s Bio Expo Live, being held July 30th through August 1st . This inaugural expo is a fantastic opportunity for biopharma companies and contract manufacturers to evaluate the latest and greatest from the comfort of your desktop or mobile device. Conveniently, we’ve broken down the lineup into Upstream Solutions July 30th, Downstream Solutions July 31st, and Quality, Analytical, and Data Solutions August 1st. It’s absolutely free to register for this series of short, digestible, and interactive sessions -- just hit the links above to register for Bio Expo Live today!
Chapters
1. Innovative Cancer Treatment Breakthrough (00:00:00)
2. Advancing Cancer Treatments (00:10:26)
3. Navigating Drug Development and Clinical Trials (00:23:36)
4. Shifting to Commercialization Efforts in Biopharma (00:34:12)
5. Bladder Cancer Treatment Costs and Manufacturing (00:39:53)
6. Immunity Bio's Comprehensive Biopharmaceutical Strategy (00:44:23)
207 episodes
Manage episode 412653666 series 2739469
We love to hear from our listeners. Send us a message.
This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical Officer at ImmunityBio, gives us a long look behind the curtain at the commercial preparations the company is making as its lead Phase 3 candidate, Anktiva, nears the goal line in non-muscle invasive bladder cancer (NMIBC). From grassroots engagement with physicians and urologists to making a global press to share clinical results, Dr. Reddy offers plenty of insight into biopharma commercial readiness, and good reason to hope for nearly a million NMIBC patients in the U.S. alone.
Register for Bioprocess Online’s Bio Expo Live, being held July 30th through August 1st . This inaugural expo is a fantastic opportunity for biopharma companies and contract manufacturers to evaluate the latest and greatest from the comfort of your desktop or mobile device. Conveniently, we’ve broken down the lineup into Upstream Solutions July 30th, Downstream Solutions July 31st, and Quality, Analytical, and Data Solutions August 1st. It’s absolutely free to register for this series of short, digestible, and interactive sessions -- just hit the links above to register for Bio Expo Live today!
Chapters
1. Innovative Cancer Treatment Breakthrough (00:00:00)
2. Advancing Cancer Treatments (00:10:26)
3. Navigating Drug Development and Clinical Trials (00:23:36)
4. Shifting to Commercialization Efforts in Biopharma (00:34:12)
5. Bladder Cancer Treatment Costs and Manufacturing (00:39:53)
6. Immunity Bio's Comprehensive Biopharmaceutical Strategy (00:44:23)
207 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.